- Home
- BYM vs MGNX Comparison
BYM vs MGNX Comparison
Compare BYM & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYM
- MGNX
- Stock Information
- Founded
- BYM 2002
- MGNX 2000
- Country
- BYM United States
- MGNX United States
- Employees
- BYM N/A
- MGNX N/A
- Industry
- BYM Investment Managers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- BYM Finance
- MGNX Health Care
- Exchange
- BYM Nasdaq
- MGNX Nasdaq
- Market Cap
- BYM 279.5M
- MGNX 257.3M
- IPO Year
- BYM N/A
- MGNX 2013
- Fundamental
- Price
- BYM $11.12
- MGNX $3.00
- Analyst Decision
- BYM
- MGNX Hold
- Analyst Count
- BYM 0
- MGNX 10
- Target Price
- BYM N/A
- MGNX $7.17
- AVG Volume (30 Days)
- BYM 60.2K
- MGNX 496.5K
- Earning Date
- BYM 01-01-0001
- MGNX 03-06-2025
- Dividend Yield
- BYM 4.49%
- MGNX N/A
- EPS Growth
- BYM N/A
- MGNX N/A
- EPS
- BYM N/A
- MGNX N/A
- Revenue
- BYM N/A
- MGNX $141,329,000.00
- Revenue This Year
- BYM N/A
- MGNX $174.73
- Revenue Next Year
- BYM N/A
- MGNX N/A
- P/E Ratio
- BYM N/A
- MGNX N/A
- Revenue Growth
- BYM N/A
- MGNX 16.68
- 52 Week Low
- BYM $9.30
- MGNX $2.91
- 52 Week High
- BYM $11.77
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- BYM 53.91
- MGNX 37.54
- Support Level
- BYM $10.76
- MGNX $3.00
- Resistance Level
- BYM $11.04
- MGNX $3.22
- Average True Range (ATR)
- BYM 0.10
- MGNX 0.17
- MACD
- BYM 0.05
- MGNX -0.02
- Stochastic Oscillator
- BYM 94.57
- MGNX 13.04
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).